GET DAILY SIGNALSEditas Medicine (EDIT) +3.6% Over the Past Month on In Vivo Trial Clearance
Key Takeaways
- EDIT gained roughly 3.6% over the last 30 days, moving from about $2.51 to around $2.60.
- The advance followed approval to initiate the Phase 1/2 Strive trial of EDIT-401 in Australia, the company's first in vivo gene-editing program to reach the clinic.
- Wells Fargo upgraded the stock to Overweight and raised its price target to $6 from $4 on the trial clearance.
- The broader quarter was largely rangebound, with shares trading roughly between $2.24 and $3.30 amid biotechnology sector volatility.
- Key near-term catalysts include initial safety and tolerability data from EDIT-401 expected in the first quarter of 2027 and a preclinical data presentation at AHA Scientific Sessions 2026.
- Editas has no approved products and remains pre-revenue, making clinical execution and cash runway central to the investment thesis.
- For additional detail, review Editas Medicine's Price Targets, Earnings, and Forecast pages.
Market Snapshot and Recent Price Action
Editas Medicine (EDIT) has moved within a fairly tight range over the past month and finished modestly higher. The stock advanced from a closing level near $2.51 on September 28 to roughly $2.60 by October 27, for a gain of about 3.6%. That upward move was driven mainly by one clear catalyst: regulatory clearance to begin human dosing of the company’s lead in vivo candidate, EDIT-401.
Over the full quarter the picture looks flatter. Shares started near $2.62 and ended close to $2.60, yet that surface stability hid some sizable swings inside the period. The stock reached toward $3.30 in late August, pulled back through September, and tested the low $2.20s in mid-October, consistent with the volatility that has marked the clinical-stage biotech and gene-editing group.
Company Overview and Competitive Landscape
Editas Medicine is a Cambridge, Massachusetts-based genome-editing firm focused on CRISPR-based therapies for serious diseases. It holds exclusive rights to the Broad Institute’s Cas12a patent estate and to Broad Institute and Harvard University’s Cas9 patent estates for human medicines, giving it a strong intellectual-property foundation.
After a strategic shift in late 2024, Editas stopped work on its ex vivo sickle cell and beta-thalassemia program reni-cel and cut its workforce by roughly 65% to focus resources on in vivo gene editing. Its lead program, EDIT-401, targets the LDLR gene to raise LDL-receptor expression and produce a durable drop in LDL cholesterol for patients with heterozygous familial hypercholesterolemia. The company competes with peers such as CRISPR Therapeutics, Intellia Therapeutics, and Beam Therapeutics. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Catalysts Behind the Move
The clearest recent driver arrived on October 8, when Editas announced Human Research Ethics Committee approval and completion of the Clinical Trial Notification process with Australia’s Therapeutic Goods Administration to start the Phase 1/2 Strive trial of EDIT-401. The filing is also under review in New Zealand. Five clinical sites have been chosen across Australia and New Zealand, and the company expects to begin dosing patients this year.
That milestone led Wells Fargo to upgrade EDIT to Overweight from Equal Weight and raise its price target to $6 from $4, pointing to a differentiated approach to lowering LDL cholesterol and the prospect of a value inflection once clinical proof-of-concept is in hand. Preclinical work has shown reductions of roughly 90% or greater in LDL cholesterol and other atherogenic lipoproteins in non-human primates.
Other developments included the early-September appointment of Dan Ory, M.D., as Chief Medical Officer and presentations at the European Society of Gene and Cell Therapy Congress in late October. The company also said new preclinical durability data for EDIT-401 will be presented at the American Heart Association Scientific Sessions in November.
Outlook and Key Items to Monitor
Going forward, the investment case for Editas rests on steady clinical progress with EDIT-401. Investors will follow the start of patient dosing, the November preclinical data at AHA Scientific Sessions 2026, and the first safety and tolerability results expected in the first quarter of 2027, with topline data from the dose-finding part of the trial due later in 2027.
Because the company is still pre-revenue, cash runway and spending discipline remain important, as does the pace of enrollment at the Australian and New Zealand sites. Broader sentiment toward clinical-stage biotech and gene-editing stocks, regulatory updates, and competitive advances from other in vivo editing programs will also matter. Analyst views have generally been constructive, though the shares stay sensitive to binary clinical and financing events. From what I see, one thing that stands out is how tightly the near-term path is tied to execution on EDIT-401.
Using AI Tools in My Research Process
In my own work I regularly look at Tickeron’s AI Screener to compare names like EDIT against peers and to spot patterns across the biotech space. The platform lets me filter on metrics that matter for clinical-stage companies and quickly see how automated signals are behaving around the sector. It has become a useful part of staying on top of developments without having to review every filing manually.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
EDIT in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 14, 2026
EDIT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 37 of 43 cases where EDIT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +9.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 179 of 224 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EDIT as a result. In 74 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for EDIT turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 42 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
EDIT moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for EDIT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.793) is normal, around the industry mean (3.037). P/E Ratio (-3.939) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which translates genome editing technology into a novel class of human therapeutics
Industry Biotechnology
Advertisement